The EMBRACE study is a prospective multi-institutional study on MRI guided adaptive brachytherapy (IGABT) in locally advanced cervix cancer (LACC). This analysis describes early to late urinary morbidity assessed by physicians and patients (PRO). A total of 1176 patients were analysed. Median follow up (FU) was 27 (1–83) months. Morbidity (CTCAE v.3) and PRO (EORTC QLQ-C30&CX24) was prospectively assessed at baseline (BL), and during FU. The most frequent symptoms were frequency/urgency, incontinence, and cystitis with grade 2–4 prevalence rates of 4.3%, 5.0% and 1.7% and grade 1–4 prevalence rates of 24.5%, 16.1% and 5.8% at 3-years. The most frequent PRO endpoints were “urinary frequency” and “leaking of urine”. Prevalence of “Quite a bit” or “very much” bother fluctuated from 14.0% to 21.5% for “frequency”, while “leaking of urine” increased from 4.6% at BL to 9.3% at 3-years. Actuarial 3-year incidence of grade 3–4 urinary morbidity was 5.3% with most events being urinary frequency, incontinence and ureteral strictures. Grade 3–4 fistula, bleeding, spasm and cystitis were all <1.0% at 3/5-years. No grade 5 toxicity occurred. Urinary grade 3–4 morbidity with IGABT was limited. Urinary morbidity grade 2–4 comprises mainly frequency/urgency, incontinence and cystitis and has considerable prevalence in PRO. Various urinary morbidity endpoints have different patterns of manifestation and time course.